nach oben

Erschienen in:

16.05.2019 | Original Article

Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: a ¹²³I-FP-CIT SPECT study

verfasst von: Andrea Pilotto, Francesca Schiano di Cola, Enrico Premi, Roberto Grasso, Rosanna Turrone, Stefano Gipponi, Andrea Scalvini, Elisabetta Cottini, Barbara Paghera, Valentina Garibotto, Maria Cristina Rizzetti, Laura Bonanni, Barbara Borroni, Silvia Morbelli, Flavio Nobili, Ugo Paolo Guerra, Daniela Perani, Alessandro Padovani

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the study was to evaluate extrastriatal dopaminergic and serotonergic pathways in patients with Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) using ¹²³I-FP-CIT SPECT imaging.

Methods

The study groups comprised 56 PD patients without dementia, 41 DLB patients and 54 controls. Each patient underwent a standardized neurological examination and ¹²³I-FP-CIT SPECT. Binding in nigrostriatal and extrastriatal regions of interest was calculated in each patient from spatially normalized images. The occipital-adjusted specific to nondisplaceable binding ratio (SBR) in the different regions was compared among the PD patients, DLB patients and controls adjusting for the effects of age, sex, disease duration and serotonergic/dopaminergic treatment. Covariance analysis was used to determine the correlates of local and long-distance regions with extrastriatal ¹²³I-FP-CIT deficits.

Results

Both PD and DLB patients showed lower ¹²³I-FP-CIT SPECT SBR in several regions beyond the nigrostriatal system, especially the insula, cingulate and thalamus. DLB patients showed significantly lower ¹²³I-FP-CIT SBR in the thalamus than controls and PD patients. Thalamic and cingulate ¹²³I-FP-CIT SBR deficits were correlated, respectively, with limbic serotonergic and widespread cortical monoaminergic projections only in DLB patients but exhibited only local correlations in PD patients and controls.

Conclusion

PD and DLB patients both showed insular dopamine deficits, whereas impairment of thalamic serotonergic pathways was specifically associated with DLB. Longitudinal studies are necessary to determine the clinical value of the assessment of extrastriatal ¹²³I-FP-CIT SPECT.

Nur mit Berechtigung zugänglich

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601. CrossRefPubMed

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88–100. https://doi.org/10.1212/WNL.0000000000004058. CrossRefPubMedPubMedCentral

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. Abolishing the 1-year rule: how much evidence will be enough? Mov Disord. 2016;31(11):1623–7. https://doi.org/10.1002/mds.26796. CrossRefPubMed

Maetzler W, Pilotto A, Apel A, Deuschle C, Kuebart G, Heinzel S, et al. In vivo markers of Parkinson’s disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody. Acta Neuropathol. 2014;128(6):893–5. PubMed

Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011;122:187–204. https://doi.org/10.1007/s00401-011-0852-9. CrossRefPubMed

Goedert M, Jakes R, Grazia M, Neurosciences C, Building CA. The synucleinopathies: twenty years on. J Parkinsons Dis. 2017;7(s1):S51–69. https://doi.org/10.3233/JPD-179005. CrossRefPubMedPubMedCentral

Roselli F, Pisciotta NM, Pennelli M, Aniello MS, Gigante A, De Caro MF, et al. Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord. 2010;25:1853–9. CrossRefPubMed

Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, et al. Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014;41(10):1938–46. https://doi.org/10.1007/s00259-014-2785-8. CrossRefPubMed

Joling M, Vriend C, van der Zande JJ, Lemstra AW, van den Heuvel OA, Booij J, et al. Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson’s disease compared with dementia with Lewy bodies. Neuroimage Clin. 2018;19:130–6. https://doi.org/10.1016/j.nicl.2018.04.009. CrossRefPubMedPubMedCentral

10.

Walker Z, Costa DC, Walker RWH, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62(9):1568–72. CrossRefPubMed

11.

Colloby SJ, O’Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, et al. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer’s disease and Parkinson’s disease. Neuroimage. 2004;23:956–66. CrossRefPubMed

12.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863–72. https://doi.org/10.1212/01.wnl.0000187889.17253.b1. CrossRefPubMed

13.

Pilotto A, Turrone R, Liepelt-Scarfone I, Bianchi M, Poli L, Borroni B, et al. Vascular risk factors and cognition in Parkinson’s disease. J Alzheimers Dis. 2016;51:563–70. https://doi.org/10.3233/JAD-150610. CrossRefPubMed

14.

Premi E, Pilotto A, Garibotto V, Bigni B, Turrone R, Alberici A, et al. Impulse control disorder in PD: a lateralized monoaminergic frontostriatal disconnection syndrome? Parkinsonism Relat Disord. 2016;30:62–6. https://doi.org/10.1016/j.parkreldis.2016.05.028. CrossRefPubMed

15.

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–707. https://doi.org/10.1002/mds.21507. CrossRef

16.

Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33:75–87. https://doi.org/10.1002/mds.27121. CrossRefPubMed

17.

Premi E, Calhoun VD, Garibotto V, Turrone R, Alberici A, Cottini E, et al. Source-based morphometry multivariate approach to analyze [123I]FP-CIT SPECT imaging. Mol Imaging Biol. 2017;19(5):772–8. CrossRefPubMedPubMedCentral

18.

Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000;10:120–31. CrossRefPubMed

19.

Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu ÖL, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50. CrossRefPubMed

20.

Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53. CrossRefPubMed

21.

Paternicó D, Premi E, Alberici A, Archetti S, Bonomi E, Gualeni V, et al. Dyslexia susceptibility genes influence brain atrophy in frontotemporal dementia. Neurol Genet. 2015;1:e24. https://doi.org/10.1212/NXG.0000000000000024. CrossRefPubMedPubMedCentral

22.

Marquie M, Locascio JJ, Rentz DM, Becker JA, Hedden T, Johnson KA, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study. Alzheimers Res Ther. 2014;6:52. https://doi.org/10.1186/s13195-014-0052-7.

23.

Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, et al. Staging of serotonergic dysfunction in Parkinson’s disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010;40:216–21. https://doi.org/10.1016/j.nbd.2010.05.028. CrossRefPubMed

24.

Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol. 2001;136:119–36. CrossRef

25.

Papapetropoulos S, Mash DC. Insular pathology in Parkinson’s disease patients with orthostatic hypotension. Parkinsonism Relat Disord. 2007;13:308–11. CrossRefPubMed

26.

Christopher L, Koshimori Y, Lang AE, Criaud M, Strafella AP. Uncovering the role of the insula in non-motor symptoms of Parkinson’s disease. Brain. 2014;137:2143–54. CrossRefPubMedPubMedCentral

27.

Fathy YY, Jonker AJ, Oudejans E, de Jong FJJ, van Dam AW, Rozemuller AJM, et al. Differential insular cortex subregional vulnerability to α-synuclein pathology in Parkinson’s disease and dementia with Lewy bodies. Neuropathol Appl Neurobiol. 2019;45:262–7. https://doi.org/10.1111/nan.12501. CrossRefPubMed

28.

Roquet D, Noblet V, Anthony P, Philippi N, Cretin B, Martin-Hunyadi C, et al. Insular atrophy at the prodromal stage of dementia with Lewy bodies: a VBM DARTEL study. Sci Rep. 2017;7:9437. https://doi.org/10.1038/s41598-017-08667-7. CrossRefPubMedPubMedCentral

29.

Liepelt-Scarfone I, Pilotto A, Müller K, Bormann C, Gauss K, Wurster I, et al. Autonomic dysfunction in subjects at high risk for Parkinson’s disease. J Neurol. 2015;262(12):2643–52. CrossRefPubMed

30.

Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018;33(3):349–58. https://doi.org/10.1002/mds.27186. CrossRefPubMed

31.

Shennhav A, Botvinick M, Cohen JD. The expected value of control: an integrative theory of anterior cingulate cortex function. Neuron. 2013;79:217–40. CrossRef

32.

Leech R, Sharp DJ. The role of the posterior cingulate cortex in cognition and disease. Brain. 2014;137:12–32. CrossRef

33.

Haber SN, Calzavara R. The cortico-basal ganglia integrative network: the role of the thalamus. Brain Res Bull. 2009;78(2-3):69–74. CrossRefPubMed

34.

Mitchell AS, Sherman SM, Sommer MA, Mair RG, Vertes RP, Chudasama Y. Advances in understanding mechanisms of thalamic relays in cognition and behavior. J Neurosci. 2014;34:15340–6. https://doi.org/10.1523/JNEUROSCI.3289-14.2014. CrossRefPubMedPubMedCentral

35.

Delli Pizzi S, Franciotti R, Taylor JP, Thomas A, Tartaro A, Onofrj M, et al. Thalamic involvement in fluctuating cognition in dementia with Lewy bodies: magnetic resonance evidences. Cereb Cortex. 2015;25:3682–9.

36.

Watson R, Colloby SJ, Blamire AM, Wesnes KA, Wood J, O’Brien JT. Does attentional dysfunction and thalamic atrophy predict decline in dementia with Lewy bodies? Parkinsonism Relat Disord. 2017;45:69–74. https://doi.org/10.1016/j.parkreldis.2017.10.006. CrossRefPubMed

37.

Gazzina S, Premi E, Turrone R, Acosta-Cabronero J, Rizzetti MC, Cotelli MS, et al. Subcortical matter in the α-synucleinopathies spectrum: an MRI pilot study. J Neurol. 2016;263:1575–82. https://doi.org/10.1007/s00415-016-8173-5. CrossRefPubMed

38.

Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol. 2006;112:253–60. CrossRefPubMed

39.

Erskine D, Ding J, Thomas AJ, Kaganovich A, Khundakar AA, Hanson PS, et al. Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies. Mov Disord. 2018;33:982–91. CrossRefPubMedPubMedCentral

40.

Stokholm MG, Iranzo A, Østergaard K, Serradell M, Otto M, Bacher Svendsen K, et al. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiol Dis. 2018;115:9–16. https://doi.org/10.1016/j.nbd.2018.02.017. CrossRefPubMed

41.

Pilotto A, Heinzel S, Suenkel U, Lerche S, Brockmann K, Roeben B, et al. Application of the Movement Disorder Society prodromal Parkinson’s disease research criteria in 2 independent prospective cohorts. Mov Disord. 2017;2:1025–34. https://doi.org/10.1002/mds.27035. CrossRef

42.

Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson’s disease: an 18F-dopa PET study. Neurobiol Dis. 2008;29:381–90. CrossRefPubMed

43.

Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. Neuroimage. 2011;56:1463–8. CrossRefPubMed

44.

Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson’s disease. J Cereb Blood Flow Metab. 2008;28:441–4. CrossRefPubMed

45.

Pilotto A, Premi E, Paola Caminiti S, Presotto L, Turrone R, Alberici A, et al. Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. Neurology. 2018;90(12):e1029–37. https://doi.org/10.1212/WNL.0000000000005161. CrossRefPubMed

46.

Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359–66. PubMed

47.

Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med. 2012;53:1087–90. https://doi.org/10.2967/jnumed.111.102277. CrossRefPubMed

48.

Matsuoka K, Yasuno F, Shinkai T, Miyasaka T, Takahashi M, Kiuchi K, et al. Test-retest reproducibility of extrastriatal binding with 7#I-FP-CIT SPECT in healthy male subjects. Psychiatry Res Neuroimaging. 2016;258:10–5. https://doi.org/10.1016/j.pscychresns.2016.10.007.

49.

Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Stevens T, et al. Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. Neurology. 2016;87:1045–51. CrossRefPubMedPubMedCentral

50.

Iranzo A, Valldeoriola F, Lomeña F, Molinuevo JL, Serradell M, Salamero M, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011;10:797–805. https://doi.org/10.1016/S1474-4422(11)70152-1. CrossRefPubMed

Titel: Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study
verfasst von: Andrea Pilotto
Francesca Schiano di Cola
Enrico Premi
Roberto Grasso
Rosanna Turrone
Stefano Gipponi
Andrea Scalvini
Elisabetta Cottini
Barbara Paghera
Valentina Garibotto
Maria Cristina Rizzetti
Laura Bonanni
Barbara Borroni
Silvia Morbelli
Flavio Nobili
Ugo Paolo Guerra
Daniela Perani
Alessandro Padovani
Publikationsdatum: 16.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04324-5

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

3′-Deoxy-3’-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies

Distinct FP-CIT PET patterns of Alzheimer’s disease with parkinsonism and dementia with Lewy bodies

Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma

Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation

Andrei Iagaru, Thomas Hope, Patrick Veit-Haibach (Eds): PET/MRI in Oncology. Current Clinical Applications